Peginterferon alfa-2b for advanced liver cancer with hepatitis B
Part of Cancer, Infections clinical trials.
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that cannot be surgically removed.
- Your liver function is good enough (Child-Pugh class A or B, score 7 or less).
- You have at least one measurable tumor.
- You test positive for hepatitis B surface antigen (meaning you have hepatitis B).
- You are physically able to care for yourself (ECOG score 0-2) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication (pegylated interferon alfa-2b) for people with hepatitis B-related liver cancer that has been completely removed by surgery or ablation. The goal is to see if this treatment can help prevent the cancer from coming back.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
This trial tests whether combining peginterferon alfa-2b with standard antiviral drugs can help people with early-stage liver cirrhosis caused by hepatitis B. The goal is to improve liver health and slow or stop the disease from getting worse.
Hear when a new HBV-HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.